ARVN vs GYRE
ARVN: Arvinas is a pioneer in the field of targeted protein degradation, leveraging its PROTAC platform to develop a new class of medicines for complex oncology and neurology diseases. GYRE: A biopharmaceutical company combining a commercial-stage fibrosis franchise in China with a U.S.-based R&D platform for targeted protein degraders and oncology therapies.
Side-by-side fundamentals
| Metric | ARVN | GYRE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $7.51 | $6.76 | |
| Market cap | $491M | $754M | |
| P/E as of 2026-10-08 | 46.82 | n/a | |
| Net margin FY2025, SEC XBRL | -30.8% | +8.5% | GYRE higher |
| Gross margin FY2025, SEC XBRL | n/a | +95.4% | |
| Operating margin FY2025, SEC XBRL | -45.1% | +9.9% | GYRE higher |
| ROE FY2025, SEC XBRL | -18.6% | +9.3% | GYRE higher |
| ROA FY2025, SEC XBRL | -11.3% | +5.9% | GYRE higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.00 | GYRE lower |
| Revenue growth (YoY) as of 2026-09-03 | -15.1% | +16.3% | GYRE higher |
| Revenue CAGR (3y) SEC XBRL | +26.0% | +4.5% | ARVN higher |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | GYRE higher |
| Beta as of 2026-09-03 | 1.04 | 1.28 | |
| 1-year return as of 2026-10-08 close | -23.0% | -7.4% | GYRE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.